Literature DB >> 20225284

Withdrawal of antiepileptic drugs after neocortical epilepsy surgery.

Kyung-Il Park1, Sang Kun Lee, Kon Chu, Keun-Hwa Jung, Eun-Kee Bae, Jin-Soo Kim, Jung Ju Lee, Seo-Young Lee, Chun Kee Chung.   

Abstract

OBJECTIVE: This study investigated the prevalence of successful antiepileptic drug withdrawal and identified predictors of seizure recurrence after antiepileptic drug reduction following resectional operation for intractable neocortical epilepsy.
METHODS: We retrospectively assessed 223 patients (100 with neocortical temporal lobe epilepsy, 69 with frontal lobe epilepsy, 23 with parietal lobe epilepsy, 25 with occipital lobe epilepsy, and 6 with multifocal epilepsy) who underwent surgery. The mean period of observation was 84.4 months (range, 24-152 months) after surgery and 72.6 months (range, 12-138 months) after initial reduction. Clinical characteristics, magnetic resonance imaging, and surgical parameters were evaluated for their potential to predict recurrence associated with antiepileptic drug withdrawal.
RESULTS: Antiepileptic drug reduction was attempted in 147 patients (65.9%), 78 (53.1%) of whom had seizure recurrence after initial reduction. Discontinuation was achieved in 73 patients (32.7%), and 59 (80.8%) of these remained seizure free until final assessment. Multivariate analysis revealed that early drug tapering, normal magnetic resonance imaging results, seizure before reduction, and longer epilepsy duration were associated with recurrence. Finally, 27.4% of patients were seizure free without drugs, and 26.9% were seizure free with drugs. Compared with preoperative status, the number of antiepileptic drugs needed decreased in 50.7% of patients, did not change in 19.3%, and increased in 30.0% after surgery.
INTERPRETATION: The complete-cure rate of intractable neocortical epilepsy by resectional surgery was 27.4%. When patients undertake early tapering, and have normal magnetic resonance imaging results, seizure before reduction, and longer disease duration, further withdrawal should be done cautiously because of the high risk of relapse.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20225284     DOI: 10.1002/ana.21884

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  8 in total

1.  Do We Need EEGs After Temporal Lobe Epilepsy Surgery, and How Many?

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2012-01       Impact factor: 7.500

2.  Surgery for epilepsy.

Authors:  Siobhan West; Sarah J Nevitt; Jennifer Cotton; Sacha Gandhi; Jennifer Weston; Ajay Sudan; Roberto Ramirez; Richard Newton
Journal:  Cochrane Database Syst Rev       Date:  2019-06-25

3.  Medication management after epilepsy surgery: opinions versus facts.

Authors:  Lara Jehi
Journal:  Epilepsy Curr       Date:  2013-07       Impact factor: 7.500

4.  Does early postoperative drug regimen impact seizure control in patients undergoing temporal lobe resections?

Authors:  Barbara Schmeiser; Bernhard J Steinhoff; Andreas Schulze-Bonhage
Journal:  J Neurol       Date:  2018-01-06       Impact factor: 4.849

5.  Stopping antiepileptic drugs: when and why?

Authors:  John D Hixson
Journal:  Curr Treat Options Neurol       Date:  2010-06-26       Impact factor: 3.598

6.  Reducing versus stopping antiepileptic medications after temporal lobe surgery.

Authors:  Ruta Yardi; Anna Irwin; Husam Kayyali; Ajay Gupta; Dileep Nair; Jorge Gonzalez-Martinez; William Bingaman; Imad M Najm; Lara E Jehi
Journal:  Ann Clin Transl Neurol       Date:  2014-02-11       Impact factor: 4.511

Review 7.  Drug-Resistant Epilepsy and Surgery.

Authors:  Jiyao Sheng; Shui Liu; Hanjiao Qin; Bingjin Li; Xuewen Zhang
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

8.  Postoperative seizure outcome and timing interval to start antiepileptic drug withdrawal: A retrospective observational study of non-neoplastic drug resistant epilepsy.

Authors:  Le Zhang; Xin-Yue Jiang; Dong Zhou; Heng Zhang; Shi-Min Bao; Jin-Mei Li
Journal:  Sci Rep       Date:  2018-09-13       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.